GENELUX CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted
GENELUX CORPORATION (GNLX) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted of 120.00 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted · last filed 2026-03-19
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2025-12-31 was 0.00 shares.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2025-09-30 was 0.00 shares.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2025-06-30 was 0.00 shares.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for the quarter ending 2025-03-31 was 120.00K shares.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2025 was 120.00K shares, a 98.40% decline from fiscal 2024.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2024 was 7.50M shares, a 1574.46% increase from fiscal 2023.
- GENELUX CORPORATION share-based compensation arrangement by share-based payment award, non-option equity instruments, granted for fiscal 2023 was 447.91K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-19 | 0.00 shares derived: sum of 3 quarters · filed 2026-03-19 | 120.00K shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-05 | 120.00K shares 10-Q · filed 2025-11-05 | 120.00K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 120.00K shares 10-Q · filed 2025-08-07 | 120.00K shares derived: sum of 3 quarters · filed 2025-08-07 | |
| 2025-03-31 | 120.00K shares 10-Q · filed 2025-05-06 | 120.00K shares derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | 7.50M shares 10-K · filed 2025-03-28 | ||
| 2024-09-30 | 7.50M shares 10-Q · filed 2024-11-14 | |||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | 106.93K shares derived: sum of 2 quarters · filed 2025-03-28 | 116.64K shares derived: sum of 3 quarters · filed 2025-03-28 | 447.91K shares 10-K · filed 2025-03-28 |
| 2023-09-30 | 106.93K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 116.64K shares derived: sum of 2 quarters · filed 2023-11-14 | 447.91K shares 10-Q · filed 2023-11-14 | |
| 2023-06-30 | 9.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 340.97K shares 10-Q · filed 2023-08-14 | ||
| 2023-03-31 | 331.27K shares 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |